nach oben

Erschienen in:

01.12.2011 | Case report

A black adrenal adenoma difficult to be differentiated from a malignant adrenal tumor by CT, MRI, scintigraphy and FDG PET/CT examinations

verfasst von: Masatoyo Nakajo, Masayuki Nakajo, Yoriko Kajiya, Atsushi Tani, Masashi Tsuruta, Satoshi Sugita, Shunsaku Fushitani, Yoshihisa Umekita

Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2011

Einloggen, um Zugang zu erhalten

Abstract

Black adrenal adenoma (BAA) is an adrenal adenoma which contains lipofuscin and has a black or brown appearance. Preoperative diagnosis of BAA is difficult because it is diagnosed by pathologic findings. We report a case of an incidentally discovered non-hyperfunctioning BAA in the left adrenal gland of a 58-year-old man. It showed an oval lipid-poor mass, 3 cm × 2 cm in size on computed tomography (CT) and magnetic resonance imaging (MRI), no avid uptake of ¹³¹I-norcholesterol and ¹²³I-meta-iodobenzylguanidine (MIBG) on scintigraphy, and intense avid uptake of ¹⁸F-fluorodeoxyglucose (FDG) on positron emission tomography–CT (PET/CT). FDG PET/CT showed that it was a hypermetabolic lesion, more intense than the activity of the liver, and the maximum standardized uptake value was 5.6 on 1-h early imaging and 8.3 on 2-h delayed imaging, suggesting a malignant tumor. BAA is a clinically rare benign adrenal adenoma, but it should be kept in mind that BAA may exhibit false-positive results for malignancy or inconclusive results for benignity with modern imaging modalities including CT, MRI, adrenal scintigraphy with radiolabelled cholesterol and radiolabelled MIBG, and FDG-PET like this case.

Robinson MJ, Pardo V, Rywlin AM. Pigmented nodules (black adenomas) of the adrenal. An autopsy study of incidence, morphology, and function. Hum Pathol. 1972;3:317–25.PubMedCrossRef

Komiya I, Takasu N, Aizawa T, Yamada T, Koizumi Y, Hashizume K, et al. Black (or brown) adrenal cortical adenoma: its characteristic features on computed tomography and endocrine data. J Clin Endocrinol Metab. 1985;61:711–7.PubMedCrossRef

Reschini E, Baldini M, Cantalamessa. A black adrenocortical adenoma causing Cushing’s syndrome not imaged by radiocholesterol scintigraphy. Eur J Nucl Med. 1990;17:185–7.PubMedCrossRef

Kameyama K, Takami H. Pigmented granules in functional black adenoma of the adrenal gland: a histochemical and ultrastructural study. Endocr Pathol. 1999;10:353–7.PubMedCrossRef

Dixon RM, Lieberman LM, Gould HR, Hafez GR. [¹³¹I]Iodocholesterol scintiscan and a rare “functional” black adenoma of the adrenal cortex. J Nucl Med. 1983;24:505–7.PubMed

Nomura K, Saito H, Aiba M, Iihara M, Obara T, Takano K. Cushing’s syndrome due to bilateral adrenocortical adenomas with unique histological features. Endocr J. 2003;50:155–62.PubMedCrossRef

Ambrosi B, Colombo P, Faglia G. Cushing’s syndrome due to a black adenoma of the adrenal gland: lack of tumour visualization by radiocholesterol scintigraphy. Eur J Nucl Med. 1994;21:1367–8.PubMedCrossRef

Mimou N, Sakato S, Nakabayashi H, Saito Z, Takeda R, Matsubara F. Cushing’s syndrome associated with bilateral adrenal adenomas. Acta Endocrinol (Copenh). 1985;108:245–54.

Okura T, Miyoshi K, Watanabe S, Kurata M, Irita J, Manabe S, et al. Coexistence of three distinct adrenal tumors in the same adrenal gland in a patient with primary alsdosteronism and preclinical Cushing’s syndrome. Clin Exp Nephrol. 2006;10:127–30.PubMedCrossRef

10.

Inomoto C, Sato H, Kanai G, Hirukawa T, Shoji S, Terauchi T, et al. Black adrenal adenoma causing preclinical Cushing’s syndrome. Tokai J Exp Clin Med. 2010;35:57–61.PubMed

11.

Tokunaga H, Miyamura N, Sasaki K, Yoshizato K, Itasaka M, Nakamaru K, et al. Preclinical Cushing’s syndrome resulting from black adrenal adenoma. A case report. Horm Res. 2004;62:60–6.CrossRef

12.

Prince EA, Yoo DC, DeLellis RA, Mayo-Smith WW. CT and PET appearance of a pigmented “black” adrenal adenoma in a patient with lung cancer. Clin Radiol. 2007;62:1229–31.PubMedCrossRef

13.

Kamiyama T, Fukukura Y, Yoneyama T, Takumi K, Nakajo M. Distinguishing adrenal adenomas from nonadenomas: combined use of diagnostic parameters of unenhanced and short 5-minute dynamic enhanced CT protocol. Radiology. 2009;250:474–81.PubMedCrossRef

14.

Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40:757–68.PubMedCrossRef

15.

Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190:1163–8.PubMedCrossRef

16.

Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194:1450–60.PubMedCrossRef

17.

Yin D. Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. Free Radic Biol Med. 1996;21:871–88.PubMedCrossRef

18.

Korobkin M, Giordano TJ, Brodeur FJ, Francis IR, Siegelman ES, Quint LE, et al. Adrenal adenomas: relationship between histologic lipid and CT and MRI findings. Radiology. 1996;200:743–7.PubMed

19.

Nakajo M, Nakabeppu Y, Yonekura R, Iwashita S, Goto T. The role of adrenocortical scintigraphy in the evaluation of unilateral incidentally discovered adrenal and juxtaadrenal masses. Ann Nucl Med. 1993;7:157–66.PubMedCrossRef

20.

Tani A, Nakajo M, Tsuchimochi S, Nakabeppu Y, Umanodan T. Adrenal incidentalomas showing unilateral concordant visualization by adrenocortical scintigraphy: comparison with adenomas in Cushing’s syndrome. Ann Nucl Med. 2000;14:205–12.PubMedCrossRef

21.

Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. ¹²³I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010;95:2596–606.PubMedCrossRef

22.

Boland GW, Blake MA, Holalkere NS, Hahn PF. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients. AJR Am J Roentgenol. 2009;192:956–62.PubMedCrossRef

23.

Bagheri B, Maurer AH, Cone L, Doss M, Adler L. Characterization of the normal adrenal gland with ¹⁸F-FDG PET/CT. J Nucl Med. 2004;45:1340–3.PubMed

24.

Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. ¹⁸F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795–9.PubMed

25.

Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, et al. ¹⁸F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058–62.PubMed

26.

Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy-initial experience. Radiology. 2006;238:970–7.PubMedCrossRef

27.

Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed ¹⁸F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547–54.PubMedCrossRef

28.

Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101–5.PubMedCrossRef

29.

Rao SK, Caride VJ, Ponn R, Giakovis E, Lee SH. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med. 2004;29:300–2.PubMedCrossRef

30.

Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K. High [¹⁸F] 2-fluoro-2-deoxy-d-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med. 2003;17:403–6.PubMedCrossRef

31.

Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer. 2001;3:59–64.PubMedCrossRef

Titel: A black adrenal adenoma difficult to be differentiated from a malignant adrenal tumor by CT, MRI, scintigraphy and FDG PET/CT examinations
verfasst von: Masatoyo Nakajo
Masayuki Nakajo
Yoriko Kajiya
Atsushi Tani
Masashi Tsuruta
Satoshi Sugita
Shunsaku Fushitani
Yoshihisa Umekita
Publikationsdatum: 01.12.2011
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 10/2011
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-011-0535-6

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A black adrenal adenoma difficult to be differentiated from a malignant adrenal tumor by CT, MRI, scintigraphy and FDG PET/CT examinations

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2011

Additional value of FDG-PET to contrast enhanced-computed tomography (CT) for the diagnosis of mediastinal lymph node metastasis in non-small cell lung cancer: a Japanese multicenter clinical study

Animal tumor models for PET in drug development

Evaluation of organ-specific glucose metabolism by 18F-FDG in insulin receptor substrate-1 (IRS-1) knockout mice as a model of insulin resistance

Novel algorithm for quantitative assessment of left ventricular dyssynchrony with ECG-gated myocardial perfusion SPECT: useful technique for management of cardiac resynchronization therapy

Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy

Tc-99m-BrIDA hepatobiliary (HIDA) scan has a low sensitivity for detecting biliary complications after orthotopic liver transplantation in patients with hyperbilirubinemia